🇺🇸 GENMAB A/SGMAB
Get GENMAB A/S filings on Telegram the moment they are published.
Follow GENMAB A/S on TelegramOne tap starts your 30-day free trial. No card needed.
Subject: 6-K — Foreign issuer report
Overview: Phase 3 RAINFOL™-02 trial results show rinatabart sesutecan (Rina-S®) met primary and key secondary endpoints for progression-free survival and overall survival in platinum-resistant ovarian cancer.
Source: SEC EDGAR · Original filing
Get filings like this in Telegram the moment they are published — for the companies you follow.
Start 30-day trial About Finterest